Document Detail


Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases.
MedLine Citation:
PMID:  10898337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In patients with bone pain due to metastatic disease, intravenous systemic radioisotope therapy may be a useful adjunct to other methods for palliating pain. METHODS: Various studies have been performed utilizing a short-lived radioisotope conjugated to a tetraphosphonate (samarium 153 lexidronam) both as an open label and as a double blinded, placebo-controlled study. Patients with varying tumor types including those of the prostate, breast, lung, and other sites were studied. Two dose levels were used (0.5 millicuries (mCi)/kg and 1.0 mCi/kg) with patients monitored for 16 weeks for efficacy (pain scores, opiod analgesic score, and quality of life) parameters and adverse events. RESULTS: All 3 studies showed that at the 1.0 mCi/kg dose level statistically significant improvement over placebo was observed by 4 weeks with relief of pain noted in many patients by 1 week. The only significant adverse event was transient myelosuppression with a nadir at 4-6 weeks and recovery by 8 weeks. Less than 10% of patients had National Cancer Institute Common Toxicity Criteria Grade III/IV bone marrow toxicity recorded. CONCLUSIONS: Systemic metabolic radiotherapy with samarium 153 lexidronam appears to be a safe and efficacious method for treating patients with bone pain. The shorter radioisotope half-life allows for a high dose rate to be delivered over a short period, which may have certain biologic benefits.
Authors:
A N Serafini
Related Documents :
11293237 - Effect of pamidronate on skeletal morbidity in myelomatosis. part 1. the results of the...
23060927 - Determination of urinary trypsin inhibitor provides insight into postoperative complica...
8738537 - High frequency of marked hyperphosphatemia during intravenous calcitriol therapy in hem...
6345147 - Human pituitary growth hormone (hgh) therapy in growth hormone deficiency.
21865997 - Reduction mammaplasty, obesity, and massive weight loss: temporal relationships of sati...
1632167 - Do anticholinergic agents affect the occurrence of postanaesthetic nausea?
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Review    
Journal Detail:
Title:  Cancer     Volume:  88     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-07-27     Completed Date:  2000-07-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2934-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Radiology and Medicine, University of Miami School of Medicine, Florida 33136, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Neoplasms / physiopathology,  radiotherapy*,  secondary*
Clinical Trials as Topic
Humans
Pain / therapy*
Palliative Care*
Samarium / adverse effects,  pharmacokinetics,  therapeutic use*
Chemical
Reg. No./Substance:
7440-19-9/Samarium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of positron emission tomography in the management of bone metastases.
Next Document:  Complications of bone metastases: surgical management.